This study aimed to evaluate and compare QFT and the tuberculin skin test (TST) for the diagnosis of active TB disease, not bacteriologically verified at the time of therapy initiation. Seventy-three patients with suspected active TB were examined. Further diagnostic steps confirmed the diagnosis of active TB in 53 persons. QFT was positive in 43 persons (81%), negative in seven (13%), and indeterminate results were found in three (6%). The sensitivity of the test was 86% in those with valid results, significantly higher than that for the TST (62%), and the correlation between the two tests was not high (55%). The QFT test is a useful addition to existing methods for the diagnosis of active TB.
Introduction
Tuberculosis (TB) remains a major health problem affecting more than eight million people annually. 1 Diagnosis of TB is usually based on a combination of anamnestic symptoms, clinical presentation, radiological and pathological changes, bacteriological findings of acid/alcohol-fast bacilli and molecular tests. 2 A definitive TB diagnosis is usually based on culture of a mycobacterium of the Mycobacterium tuberculosis complex (MTB). 3, 4 In Europe, although approximately 70 -80% of cases of pulmonary TB are confirmed by culture, generally it takes several days for culture results to become available. It is, therefore, common practice to initiate antituberculous treatment on the basis of initial clinical diagnosis, independent of subsequent culture confirmation. For those in whom infection is confirmed by culture, treatment is obviously continued, but in some patients confirmation is not possible; consequently, the accuracy of the initial clinical diagnosis is of paramount importance. Therefore, tools that can assist the clinician with the initial diagnosis of active TB are important, because antituberculous treatment takes several months and carries a risk of serious side-effects. 5 Two such diagnostic tools are the tuberculin skin test (TST) and the QuantiFERON ® -TB Gold test (QFT). The TST measures delayed-type hypersensitivity reactions to a crude mixture of mycobacterial antigens which are also present in Bacille Calmette-Guérin (BCG) vaccine strains and non-tuberculous mycobacteria. QFT is based on the KEY WORDS: ACTIVE TUBERCULOSIS; DIAGNOSTIC METHOD; QUANTIFERON ® -TB GOLD; TUBERCULIN SKIN TEST V Bartu, M Havelkova, E Kopecka QuantiFERON ® -TB Gold in the diagnosis of active tuberculosis measurement of interferon-gamma (IFN-γ) secreted from T cells previously exposed to MTB when stimulated in vitro with the MTBspecific antigens ESAT-6, CFP-10 and TB 7.7. 6 These antigens are absent from all BCG vaccine strains and most environmental mycobacteria with the exception of M. kansasii, M. marinum and M. szulgai. 7 The present study evaluated and compared the performance of QFT and the TST in the diagnosis of active pulmonary TB, in patients in whom diagnosis was made on clinical grounds or subsequently confirmed by culture of MTB.
Patients and methods

PATIENTS
Patients with symptoms compatible with active TB were enrolled into the study. Ethical approval and signed informed consent for the study was obtained. The patients were split into two groups: those who had an infection subsequently confirmed by culture of MTB; and those in whom only a clinical diagnosis was made (based on anamnestic data, symptoms, clinical examination and chest X-ray findings).
TEST PROCEDURES
The TST was performed on the volar side of the forearm according to the Mantoux method, using a 2 tuberculin unit (TU) dose of PPD RT 23. Induration > 5 mm measured after 72 h was considered positive. The whole-blood QuantiFERON ® -TB Gold in tube assay (QFT; Cellestis, Carnegie, Australia) was performed as per the manufacturer's instructions. Test results were considered positive if the IFN-γ level in the sample well containing the MTB-specific antigens minus the negative control was > 0.35 IU/ml. Both tests were performed before the administration of anti-tuberculous drugs.
STATISTICAL ANALYSIS
The data were statistically treated using analysis of variance (ANOVA). A difference was considered at the α-level of 0.5% (P ≤ 0.005).
Results
A total of 73 subjects were enrolled into the study from January 2006 to December 2006. Further investigations confirmed an infection other than TB was responsible for the symptoms in 20 patients. Data from these 20 patients, three of whom (15%) were QFT positive and 10 (50%) TST positive, were excluded from further evaluations.
The remaining 53 patients had received varied antibiotic regimens (not anti-M. tuberculosis drugs) without any response in their clinical or radiographic findings. This group comprised 17 females (mean age 45 years) and 36 males (mean age 51 years); none was HIV-positive and all were sputum smear-negative at the time of diagnosis. These individuals were clinically diagnosed as having active TB, which was subsequently supported by clinical and radiographical improvement with anti-tuberculous treatment.
The QFT results were positive in 43 of the 53 TB patients (81%), negative in seven (13%), and indeterminate in three (6%). The sensitivity of QFT, excluding those with indeterminate results, was 86% (43/50; 95% CI: 74 -93%). The TST was positive in 33 of the 53 patients, equating to a sensitivity of 62% (95% CI: 49 -74%; P < 0.005).
For the 53 patients with valid results for the two tests, both QFT and the TST were positive in 29 (55%) and negative in four cases (8%; Table 1 ). The majority of discordant results between the two tests were QFT positive but TST negative (n = 14), as reflected by the higher estimated sensitivity of the QFT test. For the three patients with indeterminate QFT V Bartu, M Havelkova, E Kopecka QuantiFERON ® -TB Gold in the diagnosis of active tuberculosis results, lymphocytopenia was detected in one person, but no evidence of factors that could result in immunosuppression were identified for the remaining two people.
During the course of anti-tuberculous therapy, a diagnosis of active TB was confirmed by culture of MTB from sputum in 22 patients. QFT was positive in 19 (86%) and TST in 12 (55%; Table 2 ).
Discussion
This study confirmed previous reports that the QFT test had greater sensitivity for detecting active TB than the 100-year-old TST. 8, 9 In the present study, the sensitivity of QFT was 86%, significantly higher than the 62% found for the TST. Although the specificity of the QFT test has been shown to be notably higher than the TST, especially in BCG-vaccinated individuals, such studies have been conducted with subjects at low risk of M. tuberculosis exposure. 6, 9 As a tool for assisting with the diagnosis of active TB, a different interpretation of 'specificity' is required; this relates to the ability of the test to discriminate between active TB and latent tuberculosis infection (LTBI). In a population with a low prevalence of LTBI, the 'specificity' of QFT for active TB diagnosis is likely to be high, as it is unaffected by the common confounders of the TST, such as BCG vaccination and exposure to non-tuberculous mycobacterium (NTM). 6, 9 However, as QFT (and the TST) does not distinguish active TB from LTBI, in a population where LTBI infection is common, the utility of QFT as a diagnostic tool for active TB is likely to be limited. In the cohort of 20 people found not to have TB, only three (15%) were QFT positive, suggesting an acceptable 'specificity' for active disease for the test in the population studied. In contrast, the TST was positive in 50% of the individuals without TB and only in a slightly higher percentage (62%) in those with TB.
Diagnosis of active TB can be difficult and inappropriate treatment has the potential to lead to serious side-effects from antituberculous drugs. 10 The advent of QFT provides an important new indirect tool to the clinician for assisting with active TB diagnosis in low to perhaps moderate LTBI prevalence populations. However, a positive QFT result is not a diagnostic standard for active TB; it is simply another aid towards diagnosis that can be highly effective in many situations. In all situations, other diagnostic steps are necessary to make a final clinical diagnosis of active TB.
In conclusion, this study confirmed that the QFT test is a useful diagnostic aid for the diagnosis of active pulmonary TB, when compared with the TST.
